Clinical trial · Observational
FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma
Molecular Correlates and Clinical Significance of Positron Emission Tomography With FET-PET in Combination With Perfusion-weighted Magnetic Resonance Imaging (PWI) in Patients With Low Grade Gliomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to compare the two imaging modalities perfusion weighted MR-imaging and FET-PET in their ability to provide an accurate histological evaluation of low grade glioma and to reveal focal abnormalities within a homogeneously appearing tumor. Additionally, therapeutic effects should be assessed during a time period of two years.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Astrocytoma | Astrocytoma | CURATED_BROADER | 0.80 |
| Oligoastrocytoma | Oligoastrocytoma | CURATED_BROADER | 0.80 |
| Oligodendroglioma | Oligodendroglioma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Group A
- description
- Patients with a suspected WHO II low grade glioma, disease progression within 1 year
- label
- Group B
- description
- Patients with a suspected WHO II low grade glioma, progression free within 1 year
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 24 months
Secondary outcomes (1)
- measure
- Progression Free survival
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * neuroradiologically suspected low grade glioma (Astrocytoma WHOI-II, Oligodendroglioma WHO II, Oligoastrocytoma WHO II) * histological verification will be obtained either by microsurgery or by stereotactic biopsy * patients older than 18 years * Karnofsky Performance Score \>=70 * pregnant or nursing female patients will not be included in this study Exclusion Criteria: * patients in whom informed consent cannot be obtained due to organic brain syndrome or insufficient language skills * patients who cannot lie quiet for a time period of app. two hours during the FET-PEt scan * medical history of a metastatic brain disease * patients in whom an MRI scan cannot be performed due to claustrophobia metallic protheses or pacemakers etc.
References
Publications (0)
Data not yet available